Skip to main content

Advertisement

SpringerLink
Log in

Overexpression of Sig1R is closely associated with tumor progression and poor outcome in patients with hilar cholangiocarcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Nonopioid Sigma1 receptor (Sig1R), which regulates various metabolism functions, has been implicated in cancers; yet, its role in hilar cholangiocarcinoma remains unclear. In the present study, we examined Sig1R expression in hilar cholangiocarcinoma (HC) tissues and explored its possible clinical values. Tissue microarray blocks containing 92 HC tissues and matched non-cancerous bile duct tissues were examined immunohistochemically for expression of Sig1R protein. Overexpression of Sig1R was found in 43 (46.7 %) of the 92 primary tumor tissues. Overexpression of Sig1R was significantly associated with poor/undifferentiation (P = 0.011), tumor invasion (P = 0.001), lymph node metastasis (P = 0.047), and advanced disease stage (P = 0.024) of HC patients. Kaplan–Meier analysis showed that patients overexpressing Sig1R had an earlier recurrence and worse overall survival than those not overexpressing Sig1R. Cox regression analysis revealed that Sig1R was an independent factor to predict HC recurrence and prognosis of HC patients. Our results suggest that Sig1R is frequently activated in human HC tissue and overexpression of Sig1R might serve as a predictor for tumor recurrence and a prognostic biomarker for HC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ramia JM. Hilar cholangiocarcinoma. World J Gastrointest Oncol. 2013;5(7):113–4.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3(1):18–34.

    PubMed Central  PubMed  Google Scholar 

  3. Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):88–98 e83; quiz e14.

    Article  PubMed  Google Scholar 

  4. Crottes D, Guizouarn H, Martin P, Borgese F, Soriani O. The sigma-1 receptor: a regulator of cancer cell electrical plasticity? Front Physiol. 2013;4:175.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995;55(2):408–13.

    CAS  PubMed  Google Scholar 

  6. Renaudo A, L’Hoste S, Guizouarn H, Borgese F, Soriani O. Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl- channels. J Biol Chem. 2007;282(4):2259–67.

    Article  CAS  PubMed  Google Scholar 

  7. John CS, Vilner BJ, Gulden ME, Efange SM, Langason RB, Moody TW, Bowen WD. Synthesis and pharmacological characterization of 4-[125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity sigma receptor ligand for potential imaging of breast cancer. Cancer Res. 1995;55(14):3022–7.

    CAS  PubMed  Google Scholar 

  8. Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O’Neill M, Howie J, Samson J, Watt S, Murray K, et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004;64(14):4875–86.

    Article  CAS  PubMed  Google Scholar 

  9. Aydar E, Onganer P, Perrett R, Djamgoz MB, Palmer CP. The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines. Cancer Lett. 2006;242(2):245–57.

    Article  CAS  PubMed  Google Scholar 

  10. Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, Meric-Bernstam F, Marcelo Aldaz C, Hortobagyi GN, et al. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat. 2004;87(3):205–14.

    Article  CAS  PubMed  Google Scholar 

  11. Skrzycki M, Czeczot H. Altered expression level of Sigma1 receptor gene in human colorectal cancer. J Recept Signal Transduct Res. 2013;33(5):313–8.

    Article  CAS  PubMed  Google Scholar 

  12. Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A, Carey LC, Rosemurgy AS. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg. 2005;190(5):810–5.

    Article  PubMed  Google Scholar 

  13. Zaydfudim VM, Clark CJ, Kendrick ML, Que FG, Reid-Lombardo KM, Donohue JH, Farnell MB, Nagorney DM. Correlation of staging systems to survival in patients with resected hilar cholangiocarcinoma. Am J Surg. 2013;206(2):159–65.

    Article  PubMed  Google Scholar 

  14. Wang D, Zhang H, Fang Z, Yu G. Annexin-1 downregulation is associated with clinical outcome in Chinese patients with hilar cholangiocarcinoma. Eur Surg Res. 2010;45(3–4):151–7.

    Article  CAS  PubMed  Google Scholar 

  15. Yu WL, Cong WM, Zhang Y, Chen Y, Wang F, Yu G. Overexpression of ATA1/SLC38A1 predicts future recurrence and death in Chinese patients with hilar cholangiocarcinoma. J Surg Res. 2011;171(2):663–8.

    CAS  PubMed  Google Scholar 

  16. Boonjaraspinyo S, Boonmars T, Wu Z, Loilome W, Sithithaworn P, Nagano I, Pinlaor S, Yongvanit P, Nielsen PS, Pairojkul C, et al. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumour Biol. 2012;33(5):1785–802.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

We declare no conflict of interest with any other person or units.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Changzheng Hospital, Shanghai, 200070, China

    Dongyun Xu, Jiejun Wang & Guanzhen Yu

  2. Department of Oncology, No. 97 Hospital of PLA, Xuzhou, 221003, Jiangsu, China

    Dongyun Xu

  3. Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

    Wei Yi

  4. Department of Oncology, Shanghai Tongren Hospital, Shanghai, 200336, China

    Ying Chen & Lijun Ma

Authors
  1. Dongyun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lijun Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiejun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guanzhen Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jiejun Wang or Guanzhen Yu.

Additional information

Wei Yi and Ying Chen have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, D., Yi, W., Chen, Y. et al. Overexpression of Sig1R is closely associated with tumor progression and poor outcome in patients with hilar cholangiocarcinoma. Med Oncol 31, 261 (2014). https://doi.org/10.1007/s12032-014-0261-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0261-8

Keywords

Search

Navigation